Our results of RNA sequencing (RNA‐seq), m6A microarray analysis and validation using clinical specimens showed that METTL3, AKT‐mRNA and AKT‐mRNA m6A were differentially expressed in MSCs from healthy donors (HD‐MSCs) and AML‐MSCs. Here, METTL3 is linked to acute myeloid leukemia.